tiprankstipranks
Johnson & Johnson sees FY25 adjusted EPS $10.75-$10.95, consensus $10.60
PremiumThe FlyJohnson & Johnson sees FY25 adjusted EPS $10.75-$10.95, consensus $10.60
2h ago
Johnson & Johnson sees FY25 operational revenue $90.9B-$91.7B
Premium
The Fly
Johnson & Johnson sees FY25 operational revenue $90.9B-$91.7B
3h ago
Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
Premium
The Fly
Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
3h ago
Nanobiotix doses first patient in CONVERGE study
PremiumThe FlyNanobiotix doses first patient in CONVERGE study
1d ago
JNJ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
JNJ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2d ago
Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
Premium
The Fly
Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
5d ago
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
PremiumThe FlyBofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
9d ago
J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
Premium
The Fly
J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
9d ago
Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
9d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100